VEGFA and retinopathy of prematurity: Since aflibercept is expected to become a popular treatment for ROP, we believe it is necessary to compare and verify the efficacy of monotherapy with the three anti-VEGF agents—bevacizumab, ranibizumab, and aflibercept—in the future.